Emerging Therapies and Supportive Care Advances in Relapsed/Refractory Multiple Myeloma

The panel looks ahead to emerging developments that may continue to shape treatment of relapsed/refractory multiple myeloma. Dr. Douglas Sborov highlights trispecific antibodies, including approaches targeting both BCMA and GPRC5D, citing encouraging efficacy and emerging tolerability data in heavily pretreated patients. Dr. Paul Richardson identifies CELMoDs as another important development and discusses data supporting their potential role in combination regimens, including activity across prespecified subgroups such as patients with high-risk disease and extramedullary disease. Dr. Jing Christine Ye emphasizes the broader movement of novel agents and combination strategies from early relapse into newly diagnosed multiple myeloma. Dr. Hans Lee highlights the OPTIC study and its evaluation of prophylactic tocilizumab to reduce cytokine release syndrome with bispecific antibody therapy, noting its potential implications for outpatient and community-based administration. Dr. Richardson also points to emerging data from the MajesTEC program, including MajesTEC-9, as evidence supporting the earlier use of bispecific therapy. Overall, the discussion highlights advances in novel agents, combination strategies, and supportive care that may expand treatment options and access.